Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Telegram Restored on Apple App Store After Temporary Removal 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Apple Restores Telegram to App Store After Content Policy Violation 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
NEW ORLEANS, April 06, 2018 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits against MiMedx Group Inc. (Nasdaq:MDXG), if they purchased the Company’s securities between the expanded period of March 7, 2013 and February 21, 2018, inclusive (the “Class Period”). These actions are pending in the United States District Courts for the Northern District of Georgia and Southern District of New York.
What You May Do
If you purchased securities of MiMedx and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqcm-mdxg/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 25, 2018.
About the Lawsuit
MiMedx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 20, 2018, MiMedx revealed it postponed its 2017 earnings report and “engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices.” Then, on February 22, 2018, media reports revealed that MiMedx had “financial ties to more than 20 doctors” that it had not disclosed to the government, which MiMedx claimed was not required.
On this news, the price of MiMedx’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
